In the last 20 years, therapeutics that directly target these cytokines (e.g., TNF or IL-17 inhibitors) completely revolutionized PsO treatment, allowing the complete clearing of psoriasis in a number of patients; however, the latter drugs account for PsA disease control only in ≤50% of patients (17). Here, TNF is linked to psoriasis.